home / stock / dsgn / dsgn news

DSGN News and Press, Design Therapeutics Inc.

Stock Information
Company Name: Design Therapeutics Inc.
Stock Symbol: DSGN
Market: NASDAQ
Website: designtx.com
Menu
DSGN DSGN Quote DSGN Short DSGN News DSGN Articles DSGN Message Board
Get DSGN Alerts

News, Short Squeeze, Breakout and More Instantly...
DSGN - Lexeo stock drops 24% amid Friedreich Ataxia study results

2024-07-15 12:03:52 ET More on Lexeo Therapeutics Lexeo Therapeutics reports Q1 results IPO Roundup: Viking Holdings, RanMarine Technology, and more Historical earnings data for Lexeo Therapeutics Financial information for Lexeo Therapeutics Read th...
DSGN - Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

2024-05-31 16:11:42 ET Summary Partial clinical hold from FDA, for use of nomlabofusp for the treatment of patients with Friedreich's Ataxia completely lifted; higher dosing of 50 mg of treatment now possible. It is expected that the global Friedreich's Ataxia market could reach $...

DSGN - Larimar stock rallies 24% on FDA removal of partial clinical hold

2024-05-20 18:17:01 ET More on Larimar Therapeutics Seeking Alpha’s Quant Rating on Larimar Therapeutics Historical earnings data for Larimar Therapeutics Financial information for Larimar Therapeutics Read the full article on Seeking Alpha For...

DSGN - Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling Patients Progressing GeneTAC TM Pipeline Programs in H...
DSGN - Design Therapeutics climbs as Piper Sandler upgrades on pipeline

2024-05-07 13:24:31 ET More on Design Therapeutics Design Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Design Therapeutics Historical earnings data for Design Therapeutics Financial information for Design T...

DSGN - PEGY, MTC and IMTE among mid-day movers

2024-05-07 12:46:58 ET More on Mid-day movers & stocks. Pineapple Energy Inc. (PEGY) Q4 2023 Earnings Call Transcript Financial information for Integrated Media Technology Financial information for Mmtec Seeking Alpha’s Quant Rating on Pineapple En...

DSGN - Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 RBC Capital Markets Healthcare Conf...
DSGN - Design Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call Transcript

2024-03-19 20:44:02 ET Design Therapeutics, Inc. (DSGN) Q4 2023 Results Conference Call March 19, 2024 4:30 PM ET Company Participants Sean Jeffries - COO Pratik Shah - Chairman, CEO Conference Call Participants Joseph Schwartz - Leerink Partners Laur...

DSGN - Design Therapeutics GAAP EPS of -$0.21 beats by $0.11

2024-03-19 16:07:28 ET More on Design Therapeutics Seeking Alpha’s Quant Rating on Design Therapeutics Historical earnings data for Design Therapeutics Financial information for Design Therapeutics Read the full article on Seeking Alpha For fur...

DSGN - Design Therapeutics Outlines Progress Across GeneTAC(TM) Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in 2025 IND Cleared for DT-168 for Treatment of Fuchs Endothelial Corneal Dystrophy (FECD) wit...
Next 10